Inozyme Pharma Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

The clock is once again running out on the US Food and Drug Administration’s rare pediatric disease priority review voucher program, and congressional action is needed within the next few weeks to tem

Drug developers will change their behavior on clinical trial diversity if the US Food and Drug Administration makes the consequences painful enough, some industry insiders say, suggesting the agency n

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI